Memphasys believes it has found a quicker, cheaper way to get its Felix sperm separation system cleared by US regulators. It could open a door to an IVF market worth about US$5.9 billion.
The final visit took place in the United States this week. The company told investors that topline results from the XanaMIA ...
Genetic Signatures and Microba Life Sciences have agreed on the principal commercial terms of a merger that would combine two ...
The Australian nuclear medicine company has agreed to lead a merger with ITM Isotope Technologies Munich SE, paying US$1.65 ...
A Melbourne biotechnology company betting on immune cell cargo as a treatment for Alzheimer's disease has enlisted one of ...
BCAL Diagnostics has started a phased rollout of Avantect Multi-Cancer in Sydney and Melbourne and plans to expand nationally ...
Anthropic has expanded its AI for Science commitment in Australia with an additional $10 million in Claude API credit grants, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results